WHO更新基药目录 增抗丙肝新药等

2015-05-13 刘玉华(译) cmt

 据Journal Watch 11日报道,日前,世界卫生组织更新了《基本药物示范目录》,增加了以下药物:        5种口服抗丙肝疗法,包括索非布韦和达卡他韦;        16种抗癌疗法,包括抗乳腺癌药物曲妥珠单抗;       &nbsp

 据Journal Watch 11日报道,日前,世界卫生组织更新了《基本药物示范目录》,增加了以下药物:
       

 
5种口服抗丙肝疗法,包括索非布韦和达卡他韦;
        
16种抗癌疗法,包括抗乳腺癌药物曲妥珠单抗;
        
5种抗肺结核疗法,包括抗多重耐药性肺结核药物贝达喹啉和迪拉马尼(delamanid)。
        
该目录纳入了基层医疗卫生系统最基本的必备药品,列出了应该优先选用的最有效、安全且符合成本效益的药物。
        
WHO注意到,目前抗丙肝的治疗方案费用太高还不能广泛使用。
         
原始出处:
         

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665244, encodeId=7b081665244c0, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20931, encryptionId=3fac20931ac, topicName=丙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67e225929577, createdName=ms24272190615788285182, createdTime=Wed Nov 04 20:08:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703659, encodeId=ade61e03659da, content=<a href='/topic/show?id=b9f04216816' target=_blank style='color:#2F92EE;'>#基药目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42168, encryptionId=b9f04216816, topicName=基药目录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f230549726, createdName=karmond, createdTime=Thu Jul 23 19:08:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23948, encodeId=a56b23948ef, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 20:15:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23301, encodeId=7430233014b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=182.149.192.**, createdTime=Wed May 13 20:04:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665244, encodeId=7b081665244c0, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20931, encryptionId=3fac20931ac, topicName=丙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67e225929577, createdName=ms24272190615788285182, createdTime=Wed Nov 04 20:08:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703659, encodeId=ade61e03659da, content=<a href='/topic/show?id=b9f04216816' target=_blank style='color:#2F92EE;'>#基药目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42168, encryptionId=b9f04216816, topicName=基药目录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f230549726, createdName=karmond, createdTime=Thu Jul 23 19:08:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23948, encodeId=a56b23948ef, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 20:15:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23301, encodeId=7430233014b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=182.149.192.**, createdTime=Wed May 13 20:04:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1665244, encodeId=7b081665244c0, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20931, encryptionId=3fac20931ac, topicName=丙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67e225929577, createdName=ms24272190615788285182, createdTime=Wed Nov 04 20:08:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703659, encodeId=ade61e03659da, content=<a href='/topic/show?id=b9f04216816' target=_blank style='color:#2F92EE;'>#基药目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42168, encryptionId=b9f04216816, topicName=基药目录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f230549726, createdName=karmond, createdTime=Thu Jul 23 19:08:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23948, encodeId=a56b23948ef, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 20:15:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23301, encodeId=7430233014b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=182.149.192.**, createdTime=Wed May 13 20:04:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-17 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1665244, encodeId=7b081665244c0, content=<a href='/topic/show?id=3fac20931ac' target=_blank style='color:#2F92EE;'>#丙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20931, encryptionId=3fac20931ac, topicName=丙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67e225929577, createdName=ms24272190615788285182, createdTime=Wed Nov 04 20:08:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703659, encodeId=ade61e03659da, content=<a href='/topic/show?id=b9f04216816' target=_blank style='color:#2F92EE;'>#基药目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42168, encryptionId=b9f04216816, topicName=基药目录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f230549726, createdName=karmond, createdTime=Thu Jul 23 19:08:00 CST 2015, time=2015-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23948, encodeId=a56b23948ef, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 20:15:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23301, encodeId=7430233014b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=182.149.192.**, createdTime=Wed May 13 20:04:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-13 182.149.192.**

    看看

    0

相关资讯

WHO发布《子宫颈癌综合防治基本实践指南(第二版)》

近日,世界卫生组织(WHO)发布了《子宫颈癌综合防治基本实践指南(第二版)》,该指南旨在帮助世界各国更好地预防和控制子宫颈癌。根据WHO,子宫颈癌是全球最致命但最容易预防的女性癌症类型。在全球范围内,每年有超过27万人死于子宫颈癌,其中高达85%的死亡病例发生在发展中国家。 《子宫颈癌综合防治基本实践指南(第二版)》于2014年12月3日在澳大利亚墨尔本举行的《世界癌症领袖峰会》上发布。该指

WHO发布应对埃博拉疫情临时性推荐意见

已出现埃博拉病毒传播国家 1. 应宣布国家处于紧急状态,向公众提供相关信息,采取措施应对疫情。 2. 卫生部长等卫生相关领导人应在埃博拉紧急应对中起主导作用。 3. 国家应启动灾害/应急处置系统,建立应急指挥中心,协调各相关部门、机构,保证埃博拉控制措施的有效实施。 4. 充分利用社区力量,使社区在病例识别、接触者追踪及风险教育方面起

世卫组织公布埃博拉疫情新报告

图片来源:LOREDANA SIANI/OKAIROS 在世卫组织(WHO)公布西非埃博拉疫情发生6个月后,WHO近日再次公布了一项新的研究报告,报告警示埃博拉疫情正在快速恶化,甚至可能成为“西非人群中从未被预期到的一场大规模瘟疫”。 位于美国亚特兰大市的国家疾控中心(CDC)同时发布了一项关于这一致命病毒蔓延的新模型,其演示分析估计,最坏的情况是到2015年1月,超过14

WHO建议减少糖的摄入量以降低肥胖与龋齿的发病率

WHO建议减少糖的摄入量以降低肥胖与龋齿的发病率关键词:WHO 糖 糖摄入量 肥胖 龋齿 2015年3月4日世界卫生组织——WHO声明,成年人和儿童必须将糖摄入量减到北美和西欧的一半,某些地方甚至需要减掉更多,以降低糖所导致的肥胖和龋齿的危险。联合国机构的专家告诉记者,新的指导方针指出,对于成年人来说,糖的摄入量应该减少到日常能量摄入的10%以下或减少到约50毫克或12茶匙。如果能将糖摄入量能减

中国疫苗监管体系获世卫组织认可

北京,2014年7月4日 - 世界卫生组织(WHO)总干事陈冯富珍博士今天宣布:经世卫组织专家评估,中国疫苗监管体系(NRA),即中国国家食品药品监督管理总局(CFDA),达到或超过世界卫生组织的全部标准。“我们高兴地宣布世卫组织对中国疫苗监管体系的评估结果。这是中国国家食品药品监督管理总局及其直属单位的重要成就。”陈冯富珍博士表示。“通过评估,世卫组织对中国国产疫苗的质量、安全性和有效